Weekly shot may boost growth in teens with dwarfism

NCT ID NCT06732895

Recruiting now Disease control Sponsor: Ascendis Pharma A/S Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 23 times

Summary

This study tests a weekly injection called navepegritide in 24 adolescents aged 12-18 with achondroplasia, the most common form of dwarfism. The goal is to see if it safely increases growth rate over one year compared to a placebo. Participants will receive either the drug or an inactive shot and have their height measured regularly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ascendis Investigational Site
RECRUITING

Montreal, H3T 1C5, Canada
Ascendis Investigational Site
RECRUITING

Copenhagen, 2100, Denmark
Ascendis Investigational Site
RECRUITING

Paris, 75743, France
Ascendis Investigational Site
RECRUITING

Dublin, D01 YC76, Ireland
Ascendis Investigational Site
RECRUITING

Norwich, NR4 7UY, United Kingdom

Conditions

Explore the condition pages connected to this study.

ACHONDROPLASIA